Cargando…

Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant

Cytomegalovirus (CMV) reactivation is one of the most common infections affecting allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies have been evaluated for the prevention of CMV reactivation, their toxicity profile makes them unfavorable for use as primary pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Shigle, Terri Lynn, Handy, Victoria Wehr, Chemaly, Roy F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318821/
https://www.ncbi.nlm.nih.gov/pubmed/32637057
http://dx.doi.org/10.1177/2040620720937150
_version_ 1783550937955041280
author Shigle, Terri Lynn
Handy, Victoria Wehr
Chemaly, Roy F.
author_facet Shigle, Terri Lynn
Handy, Victoria Wehr
Chemaly, Roy F.
author_sort Shigle, Terri Lynn
collection PubMed
description Cytomegalovirus (CMV) reactivation is one of the most common infections affecting allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies have been evaluated for the prevention of CMV reactivation, their toxicity profile makes them unfavorable for use as primary prophylaxis; thus, they are routinely reserved for the treatment of CMV viremia or CMV end-organ disease. Pre-emptive CMV monitoring strategies have been widely accepted, and although they have been helpful in early detection, they have not affected the overall morbidity and mortality associated with CMV. Letermovir is a novel agent that was approved for primary prophylaxis in CMV-seropositive adult allogeneic hematopoietic cell transplant recipients. This review focuses on letermovir’s novel mechanism; clinical trials supporting its United States Food and Drug Administration (FDA) approval and subsequent follow-up analyses; clinical considerations, with an emphasis on pharmacology; and lessons learned from solid organ transplant recipients, as well as potential future directions.
format Online
Article
Text
id pubmed-7318821
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-73188212020-07-06 Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant Shigle, Terri Lynn Handy, Victoria Wehr Chemaly, Roy F. Ther Adv Hematol Review Cytomegalovirus (CMV) reactivation is one of the most common infections affecting allogeneic hematopoietic cell transplant recipients. Although available anti-CMV therapies have been evaluated for the prevention of CMV reactivation, their toxicity profile makes them unfavorable for use as primary prophylaxis; thus, they are routinely reserved for the treatment of CMV viremia or CMV end-organ disease. Pre-emptive CMV monitoring strategies have been widely accepted, and although they have been helpful in early detection, they have not affected the overall morbidity and mortality associated with CMV. Letermovir is a novel agent that was approved for primary prophylaxis in CMV-seropositive adult allogeneic hematopoietic cell transplant recipients. This review focuses on letermovir’s novel mechanism; clinical trials supporting its United States Food and Drug Administration (FDA) approval and subsequent follow-up analyses; clinical considerations, with an emphasis on pharmacology; and lessons learned from solid organ transplant recipients, as well as potential future directions. SAGE Publications 2020-06-24 /pmc/articles/PMC7318821/ /pubmed/32637057 http://dx.doi.org/10.1177/2040620720937150 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Shigle, Terri Lynn
Handy, Victoria Wehr
Chemaly, Roy F.
Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
title Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
title_full Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
title_fullStr Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
title_full_unstemmed Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
title_short Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
title_sort letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318821/
https://www.ncbi.nlm.nih.gov/pubmed/32637057
http://dx.doi.org/10.1177/2040620720937150
work_keys_str_mv AT shigleterrilynn letermoviranditsroleinthepreventionofcytomegalovirusinfectioninseropositivepatientsreceivinganallogeneichematopoieticcelltransplant
AT handyvictoriawehr letermoviranditsroleinthepreventionofcytomegalovirusinfectioninseropositivepatientsreceivinganallogeneichematopoieticcelltransplant
AT chemalyroyf letermoviranditsroleinthepreventionofcytomegalovirusinfectioninseropositivepatientsreceivinganallogeneichematopoieticcelltransplant